Search
sevelamer (Renagel, Genzyme, Renvela)
calcium & aluminum-free phosphate-binder
Indications:
- reduction of serum phosphorus in patient with end-stage renal disease
- renal osteodystrophy [3]
Contraindications:
safety in lactation: +
Dosage:
1) 2-4 tablets with meals
2) adjust dose for target serum phosphorus of < 6 mg/dL
Tabs: 403 mg.
Renagel is hydrochloride, Renvela is carbonate salt
Pharmacokinetics:
- not absorbed following oral administration
Adverse effects:
1) dyspepsia
2) nausea/vomiting
Mechanism of action:
1) calcium & aluminum-free phosphate-binder within intestines
2) cross-linked poly(allylamine hydrochloride)
3) reduces cholesterol & LDL cholesterol
Interactions
drug interactions
General
phosphate binder
Database Correlations
PUBCHEM cid=159247
References
- Micromedex vol 102
- Prescriber's Letter 14(12): 2007
New Drug: Renvela (Sevelamer Carbonate)
Detail-Document#: 231206
(subscription needed) http://www.prescribersletter.com
- Deprecated Reference
Components
Ca+2